The arachidonate lipoxygenase (LO) product, 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), has been implicated as a key contributor to the pathogenesis of atherosclerosis, hypertension, and diabetic nephropathy (1-4). 12-LO expression has been detected in renal vascular and glomerular cells, and these cells have the capacity to produce 12(S)-HETE (5-8). In addition to its involvement in glomerular inflammation and vascular smooth muscle cell growth, 12(S)-HETE is a renal vasoconstrictor (5,(8)(9)(10). 12(S)-HETE decreases renal blood flow and glomerular filtration independent of cyclooxygenase (COX) activity (9). Additionally, the action of angiotensin II on the renal vasculature involves participation of the LO pathway. A previous study by our laboratory demonstrated that the afferent arteriolar constriction to angiotensin II is attenuated in the presence of 12-LO inhibition (11). In contrast, norepinephrine-mediated renal microvascular vasoconstriction was unaffected by 12-LO inhibition (11). One aim of the current study was to determine renal microvascular production of COX metabolites and 12(S)-HETE in response to angiotensin II and norepinephrine.Although the importance of 12(S)-HETE in renal and cardiovascular disease is now established, the mechanism by which 12(S)-HETE constricts the preglomerular vasculature remains to be identified. It is known that 12(S)-HETE causes depolarization of the vascular smooth muscle cell membrane and may act through activation of protein kinase C to constrict blood vessels (9). Depolarization of vascular smooth muscle should activate L-type calcium channels. Therefore, a second aim of the present study was to determine the contribution of L-type calcium channel activation to the 12(S)-HETE mediated renal vasoconstriction.
METHODS
Renal microvessel 12(S)-HETE and COX metabolite productionMale Sprague-Dawley rats were anesthetized with sodium pentobarbital (40 mg/kg body weight ip), and the abdominal cavity was